Learn about the groundbreaking cardiovascular care offered at the Mount Sinai Health System. Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital is ranked No. 4 in the nation for Cardiology, Heart and Vascular Surgery by U.S. News & World Report® for 2024-25, and is recognized internationally as a leader in advancing all aspects of cardiology care, cardiac surgery, and cardiovascular research. Our team of award-winning physicians is expanding the field of knowledge in cardiovascular medicine, including treatments for arrhythmias, coronary artery disease, heart failure, valvular disease, and vascular disease.
Learn about the groundbreaking cardiovascular care offered at the Mount Sinai Health System. Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital is ranked No. 4 in the nation for Cardiology, Heart and Vascular Surgery by U.S. News & World Report® for 2024-25, and is recognized internationally as a leader in advancing all aspects of cardiology care, cardiac surgery, and cardiovascular research. Our team of award-winning physicians is expanding the field of knowledge in cardiovascular medicine, including treatments for arrhythmias, coronary artery disease, heart failure, valvular disease, and vascular disease.
Cardiovascular disease remains a dominant global health burden, rooted in complex molecular and cellular pathobiology that evolves across an individual’s lifespan. Yet advances at the intersection of biomedical research and technology ...
The study, the largest of its kind, found that patients with long COVID may exhibit inflammation in the heart and lungs for up to a year after SARS-CoV-2 infection.
The program has consistently set standards in cardiac practice and cardiovascular research, and trainees have the opportunity to treat an extraordinarily wide range of patients.
Mount Sinai Fuster Heart Hospital is renowned internationally in all facets of cardiology care, cardiac surgery, and advanced research. Global leaders in cardiology, the team of award-winning physicians has invigorated the science of cardiovascular ...
In 2024, the physicians and scientists of Mount Sinai Fuster Heart Hospital demonstrated day after day—with outstanding cardiology care, cardiac surgery, and research—all of the achievements that make us a world leader in the field.
The five-year, 1,200-patient study is funded by an institute that provides patients, caregivers, and clinicians with evidence-based information to make better-informed health care decisions.
By creating the first mouse model, the team gained critical insights into the processes that trigger FMD, suggesting a potential therapeutic avenue for the challenging disease.
The study is the first to show important safety outcomes with pulsed field ablation in a large patient population, including no significant risk of esophageal damage.
The first-of-its-kind SMART trial compared the hemodynamic performance and clinical outcomes of the two most widely used valve systems: the EVOLUT self-expanding supra-annular device and the SAPIEN balloon-expandable valve.
The novel findings emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of clinical management after a cardiac event.
Two studies describe a new approach for managing coronary calcium and calcified nodules with an evidence-based algorithm guided by optical coherence tomography imaging.
Mount Sinai Fuster Heart Hospital took a leadership role in a pivotal trial of tricuspid transcatheter edge-to-edge repair, and Mount Sinai is among the highest-volume centers for mitral valve and tricuspid T-TEER procedures in the United States.
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, ...
The new clinical trial, led by Valentín Fuster, MD, PhD, is responding to clinical evidence that the atherosclerotic process starts early in life, and even in young adults deemed otherwise healthy can pave the way for cardiovascular events.
Withdrawing aspirin one month after PCI in high-risk heart patients and keeping them on ticagrelor alone safely improves outcomes and reduces major bleeding by more than half when compared to dual antiplatelet therapy, the current standard of care.
Routine use of an orbital atherectomy device to remove calcium from severely blocked coronary arteries before patients undergo cardiac stenting procedures does not improve outcomes, a Mount Sinai-led study has found.
The progression of atherosclerosis in people who have no symptoms of it is independently associated with the risk of dying from any cause, according to a new study led by researchers from Mount Sinai Fuster Heart Hospital, published September ...
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.
Roxana Mehran, MD, Professor of Medicine (Cardiology), and Population Health Science and Policy of Mount Sinai Fuster Heart Hospital, has been named the incoming Vice President of the American College of Cardiology (March 2025).
Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF), according to the largest study of its kind on this new technology, led by the Icahn School of Medicine at Mount Sinai.
The Cardiac Catheterization Laboratory at The Mount Sinai Hospital is among the highest volume centers, yet also among the safest interventional catheterization laboratories in the United States.
Using an advanced artificial intelligence tool, researchers at the Icahn School of Medicine at Mount Sinai have identified rare coding variants in 17 genes that shed light on the molecular basis of coronary artery disease (CAD), the leading ...
The European Society for Clinical Investigation (ESCI) is awarding Valentin Fuster, MD, PhD, President of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, its ESCI Distinguished Medal for 2024. He received this honor ...
A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol ...
Valentín Fuster, MD, PhD, MACC, President of Mount Sinai Fuster Heart Hospital, was awarded the WHF Lifetime Achievement Award 2024 from the World Heart Federation to publicly recognize his remarkable contributions to the mission of the ...
A neural network-based electrocardiogram (ECG) interpretation algorithm developed at Mount Sinai is designed to predict the presence of right ventricular dilation and dysfunction based on cardiac magnetic resonance imaging (MRI) reference ...
Mount Sinai Fuster Heart Hospital is renowned internationally in all facets of cardiology care, cardiac surgery, and advanced research. Global leaders in cardiology, the team of award-winning physicians has invigorated the science of cardiovascular ...
For Mount Sinai Fuster Heart Hospital, 2023 was truly a landmark year. The foremost landmark is our new name: In October, Mount Sinai Heart was renamed to honor Valentin Fuster, MD, PhD, the man who built Mount Sinai’s cardiovascular program ...
A therapeutic pathway targeting ANGPTL3 holds promise for patients with severe hypercholesterolemia who do not achieve their low-density lipoprotein cholesterol thresholds despite treatment with lipid-lowering therapies.
Investigators at CVRI continued to advance discovery and innovation in lifestyle and prevention, systems physiology and bioengineering, and genetic medicine.
The team has significantly advanced knowledge on psychosocial stress and cardiovascular disease by identifying connections between the nervous, immune, and vascular systems.
The three-drug cardiovascular polypill, developed and studied under the leadership of Valentin Fuster, MD, PhD, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing ...
The Cardiac Catheterization Laboratory at The Mount Sinai Hospital pioneered two innovative procedures. The first involved employing the world’s smallest heart pump system to provide temporary mechanical circulatory support during high-risk ...
The multisite—and possibly paradigm-shifting—study will assess whether pairing coronary CT angiography with an AI-enabled algorithm to classify the build-up of atherosclerotic plaque into stages is superior to the standard of care.
Dr. Dangas, Director of Cardiovascular Innovation at the Zena and Michael A. Wiener Cardiovascular Institute at Icahn Mount Sinai and Chief of Cardiology at Mount Sinai Queens, is the 46th president of SCAI.
The Cardiac Catheterization Laboratory at The Mount Sinai Hospital has received for the third consecutive year the highest three-star rating, one of the most rigorous and highly respected measures for evaluating the quality of transcatheter ...
Hereditary transthyretin amyloidosis significantly increases the risk of heart disease and disproportionately affects African American and LatinX people in the United States, yet few members of the public are aware of it.
The name change honors Valentin Fuster, MD, PhD, who built Mount Sinai’s cardiovascular program into one of the world’s leading heart centers while advancing cardiovascular medicine around the globe.
Mount Sinai Health System announced on 10/26/23 that “Mount Sinai Fuster Heart Hospital” is the new name for its top-ranked heart service, formerly known as Mount Sinai Heart.
PET MPI quantifies left ventricular ejection fraction (LVEF) at peak stress, offering diagnostic and prognostic insights. The newly introduced PET LVEF reserve (LVEF-R) measures the difference between stress and rest LVEF, creating an ...
Low socioeconomic status can negatively impact children’s health in preschool, along with their ability to follow specialized health education intervention programs, Mount Sinai researchers found in an international study focused on health ...
The Icahn School of Medicine at Mount Sinai announced today that it has signed a memorandum of understanding with the Brazilian Clinical Research Institute (BCRI) to focus on advancing cardiovascular disease research, innovation, and medical education.
Using optical coherence tomography (OCT) to guide stent implantation during percutaneous coronary intervention (PCI) may be safer and lead to better outcomes for heart disease patients than angiography-guided PCI alone, the most commonly used method.
Mount Sinai Heart, Mount Sinai Children’s Heart Center, and the Mount Sinai Adult Congenital Heart Disease Center are proud to present a special two-day academy on “Grown-Up Childhood Heart Disease for the Adult Cardiologist” in partnership ...
Polypill includes three active ingredients and is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this population.
A study offers evidence that aggressive lipid lowering with a PCSK9 inhibitor, along with a statin, can significantly reduce that threat and potentially help doctors identify patients who would benefit most from treatment to change their ...
Mount Sinai Queens today announced the opening of a new cardiac catheterization lab that will provide rapid and comprehensive care to hundreds of heart patients every year for life-threatening emergencies and scheduled cardiac procedures.
Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status.
Twenty-six weeks of PCSK9 inhibitor therapy on top of maximally tolerated statins increases markers of plaque stability in patients with stable coronary artery disease, according to the YELLOW III trial, led by Annapoorna S. Kini, MD, ...
Higher concentrations of lipoprotein(a) have long been associated with atherosclerosis and aortic stenosis, but no drug therapies that lower this concentration are approved. Olpasiran shows promise.
To improve outcomes of STEMI patients, Mount Sinai Heart developed a secure mobile app to streamline real-time communication and coordination between multiple teams.
A unique Mount Sinai study focused on a multiethnic, underserved community in Harlem found that young non-Hispanic Black adult participants were twice as likely to have atherosclerosis as young Hispanic adults.
In a milestone in cardiovascular medicine, a three-drug medication known as a “polypill” was found effective in preventing adverse events such as heart attacks or stroke in people who have previously had a heart attack...
The Center for Inherited Cardiovascular Diseases was established in 2022, positioning Mount Sinai Heart at the forefront of cardiovascular genomic medicine.
Mount Sinai Heart is launching a multispecialty Women's Heart and Vascular Center, with clinics specifically designed to screen, assess, and educate women about their level of individual risk
Chronic, insufficient sleep can negatively affect immune cells, which may lead to inflammatory disorders and cardiovascular disease, according to a study from the Icahn School of Medicine at Mount Sinai.
Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the most serious type of heart attacks who undergo PCI, and can lower the risk of death or major bleeding by 31 percent.
Patients identified by nuclear stress testing as having severe stress-induced myocardial ischemia are likely to benefit from heart bypass surgery or angioplasty, while those with mild or no ischemia are not.
Globally acclaimed cardiologist Valentin Fuster, MD, PhD, has been named President of Mount Sinai Heart, a newly created position. Deepak L. Bhatt, MD, MPH, a top expert in cardiovascular medicine and interventional cardiology, has been named Director.
The Cardiovascular Research Institute is building on Mount Sinai’s legacy of discovery and innovation with a renewed focus on lifestyle and prevention, systems physiology and bioengineering, and genetic medicine.
The study is the first to look at COVID-19 vaccination status and outcomes in patients with heart failure and has indicated significant protective effects in this high-risk patient population.
Mount Sinai researchers help identify previously unknown genetic causes of primary lymphedema, thoracic aortic aneurysm disease, and congenital deafness.
Message From the President: I am honored to update you on a year of high achievement at Mount Sinai Heart, which is driven by a unified mission—better control and prevention of heart disease.
A novel type of therapy, known as ANGPTL3 inhibitor therapy, was effective in lowering triglycerides in certain types of patients with severe hypertriglyceridemia (sHTG) who had a prior episode(s) of acute pancreatitis.
High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation.
Join Valentín Fuster, MD, PhD, MACC and a panel of experts for a discussion on the top late-breaking clinical trials released during the ACC 2023 Conference.
Fasting may be detrimental to fighting off infection, and could lead to an increased risk of heart disease, according to a new study by the Icahn School of Medicine at Mount Sinai.
The award recognizes Dr. Mehran’s outstanding record of effectively mentoring women cardiologists and underscores the importance of mentoring in the professional development of women.
Mount Sinai Health System’s globally acclaimed cardiologist Valentín Fuster, MD, PhD, has been named President of Mount Sinai Heart, a newly created position, effective Sunday, January 1, 2023.
The TCT Career Achievement Award has been presented to Valentin Fuster, MD, PhD, today, September 17, 2022, at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF).
In a milestone in cardiovascular medicine, a three-drug medication known as a “polypill” was found effective in preventing adverse events such as heart attacks or stroke in people who have previously had a heart attack
The Cardio-Oncology Program at The Mount Sinai Hospital, under the directorship of Gagan Sahni, MD, has been awarded Gold Center of Excellence status. This is the highest designation of certification from the International Cardio-Oncology ...
A unique Mount Sinai study focused on a multiethnic, underserved community in Harlem found that young non-Hispanic Black adult participants were twice as likely to have atherosclerosis as young Hispanic adults.
Heart failure patients who are unvaccinated against SARS-CoV-2, the virus that causes COVID-19, are three times more likely to die if infected with the virus compared to fully boosted heart failure patients, according to new research out of Mount Sinai Heart.
The specialized and complex Ross procedure is the optimal treatment for adolescents and adults with a diseased aortic valve, replacing it with the patient’s own pulmonary valve, resulting in improved long-term life expectancy and less ...
Transcatheter mitral valve repair for heart failure patients with mitral regurgitation can reduce the long-term rate of hospitalizations by almost 50 percent, and death by nearly 30 percent, compared with heart failure patients who don’t undergo the procedure.
Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital has again earned the American College of Cardiology’s Transcatheter Valve Certification. Mount Sinai is the only cardiac center in New York City and one of six in New York State ...
Mount Sinai Fuster Heart Hospital is renowned internationally in all facets of cardiology care, cardiac surgery, and advanced research. Global leaders in cardiology, the team of award-winning physicians has invigorated the science of cardiovascular ...
A journey that began 10 years ago for Vivek Reddy, MD, with his implantation of the country’s first single-chamber leadless cardiac pacemaker, reached fruition as the FDA approved the first dual-chamber device for the treatment of bradycardia, ...
A multidisciplinary team is investigating risk factors for malignant ventricular arrhythmias in mitral valve prolapse, which can lead to sudden death in a small but significant subset of patients.
The department received the highest three-star ratings across all measurable categories in the STS Adult Cardiac Surgery Database, the national benchmark to assess excellence in cardiovascular surgery outcomes.
Dr. Randolph Martin discusses the 2023 AATS Mitral Conclave with Co-Program Director, Dr. David Adams. Over 900 registrants from over 50 countries came together to share best practices for taking care of patients with mitral valve disease
Randolph Martin, MD, speaks with Ismail El-Hamamsy, MD, and Maral Ouzounian, MD, about the lifetime management of patients with aortic stenosis and aortic insufficiency
Drs. Randolph Martin, Gilles Dreyfus, and Anelechi Anyanwu, discuss the impact of Carpentier’s milestone paper “The French Correction” 40 years after its publication
A breakthrough study found that the TriClip™ transcatheter edge-to-edge repair (TEER) system was safe for patients with severe tricuspid regurgitation, reduced the severity of tricuspid regurgitation, and was associated with an improvement in quality of life.
The Society for Cardiovascular Angiography & Interventions (SCAI) has named George Dangas, MD, PhD, Professor of Medicine (Cardiology), and Surgery, at the Icahn School of Medicine at Mount Sinai as its new President.
First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI).
For the 24th consecutive year, The Mount Sinai Hospital’s Cardiac Catheterization Laboratory or its interventionalists have received the highest two-star safety rating from the New York State Department of Health (NYSDOH) for percutaneous ...
Deepak Bhatt, MD, MPH, Director of Mount Sinai Heart, outlines the results for the HALO trial, explaining that a post hoc analysis revealed that a cluster of patients in one of the study arms was nonadherent; when results for adherent ...
Mount Sinai Heart is launching a multispecialty Women's Heart and Vascular Center, with clinics specifically designed to screen, assess, and educate women about their level of individual risk
Pulsed field ablation represents a potential paradigm shift in AF ablation. The modality is a more tissue-specific form of energy delivery than thermal, involving the application of high-intensity direct current pulses of short duration ...
Chronic, insufficient sleep can negatively affect immune cells, which may lead to inflammatory disorders and cardiovascular disease, according to a new study from the Icahn School of Medicine at Mount Sinai.
A large-scale international study led by Mount Sinai has yielded the first risk score that can help predict mortality for patients with atrial fibrillation (AFib) who have undergone a successful transcatheter aortic valve replacement (TAVR) ...
This large study of patients undergoing PET MPI demonstrated that although reduced MBFR was more prevalent in women compared with men, there were no sex-specific differences in the prognostic value of reduced MBFR.
Use of anatomic testing such as coronary artery calcium scoring (CACS) of 0 to avoid myocardial perfusion imaging in symptomatic patients could lead to missing microvascular dysfunction in 4 out of 10 patients, a finding associated with a high mortality risk.
The Ross procedure may be a more favorable option for aortic valve replacement among patients under 50 years old than more standard mechanical or biological replacements, according to a study from Mount Sinai Heart.
A scientific statement outlining unique considerations and suggestions for managing heart failure patients during the COVID-19 pandemic was issued in September 2021 by the Heart Failure Society of America, and Anuradha Lala, MD, Assistant ...
An updated risk score can help predict possible contrast-associated acute kidney injury (CA-AKI) among patients undergoing percutaneous coronary intervention (PCI), according to Mount Sinai Heart researchers, led by Roxana Mehran, MD, ...
A study showing the safety and effectiveness of a leadless cardiac pacemaker for right ventricular pacing has set the stage for research into a novel dual-chamber device that would serve a significantly broader population of patients with ...
Use of a novel technique called the quantitative flow ratio (QFR) to precisely identify and measure the severity of artery blockages can lead to significantly improved outcomes after percutaneous coronary intervention (PCI), according ...
Filip Swirski, PhD, an internationally recognized leader in cardiovascular immunology research, is the inaugural Director of the new Cardiovascular Research Institute.
The Icahn School of Medicine at Mount Sinai will help lead and launch the first clinical trial focusing on women and minority populations to determine which coronary revascularization procedure best improves their survival and quality of life.
Ismail El-Hamamsy, MD, PhD, Professor of Cardiovascular Surgery, discusses The Ross Procedure, providing a step-by-step guide to optimize long-term durability and reviews what is new in the literature on this procedure.
Join Ismail El-Hamamsy, MD, PhD, as he discusses the latest in aortic valve surgery in non-elderly adults, and reviews what is new in the literature on this topic
In this study published by the ACC, researchers analyzed the association between in-hospital anticoagulation administration and mortality among patients hospitalized with COVID-19.
Dr. Adams presents Dr. Anyanwu, who explores the options and tradeoffs in aortic valve replacement, and the issues that should be discussed between doctor and patient.
Get an overview from Dr. Fuster of some of the most impactful studies presented at the national meeting of the American College of Cardiology last year in Orlando.
Mount Sinai Heart at The Mount Sinai Hospital has earned The Joint Commission’s Comprehensive Cardiac Center (CCC) Certification, becoming one of only four cardiac organizations in the United States to hold the prestigious honor.
